NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Annual ending 2027-03-31 | ||
| Revenue | — | 35.1M |
| EPS | — | -17.1 |
Management figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise and manage capital to fund operations | A primary condition in Modular Medical Inc's published investment case. The stated target is Raise approximately $3.38 million in 2026-Q4 and maintain $0.35 million credit facility in 2026-Q1. | Intact | Fail to raise $3.38 million or lose $0.35 million credit facility by 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q2 via press release announcing a $3.4 million registered direct offering. Financials show ongoing net losses and negative operating income, indicating continued need for capital. The equity offering aligns with management's capital allocation focus but delivery is early with limited financial improvement yet. Delivery assessment Oct 24, 2026 |
Stabilize executive leadership and governance | A supporting condition in Modular Medical Inc's published investment case. The stated target is No major leadership disruptions and stable governance in 2026. | Intact | Significant leadership turmoil or governance issues in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses and negative cash flow | A primary condition in Modular Medical Inc's published investment case. The stated target is Operating income better than -$5.68 million and cash flow better than -$5.82 million by 2026-Q4. | Broken | Operating income or cash flow worse than targets in 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.9M in 2025-Q3 to -$6.5M in 2027-Q1, with cash from operations negative around -$5.4M to -$6.0M. The trajectory shows persistent operating losses and negative cash flow, indicating limited progress in reducing losses. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established compounder. The long-term thesis is currently intact, but confidence is low because operating losses and negative operating cash flow have persisted.
The evidence snapshot provides no valuation measure or direct estimate of market expectations, so whether MODD is cheap, fair, or expensive versus peers is unclear. The key expectations gap is whether the business can reduce losses and its need for outside capital; the evidence shows limited progress so far.
Near term, a next-quarter earnings miss is a significant risk, with a run of consecutive misses and the company’s smaller size cited as concerns. Over the multi-year view, management has repeatedly named loss and cash-flow control as priorities, but operating losses and negative cash from operations remain persistent. A recent equity offering and debt issuance show ongoing attention to funding, while financial improvement remains limited.
The multi-year thesis hinges on whether MODD can improve operating losses and cash flow while managing its capital needs. Near term, weakening jobs data could weigh on cyclical names, while continued strength from Healthcare bellwethers such as ABT, MDT, and SYK could sustain sector support. Misses or lower guidance from those companies could weaken that support.
For the next 1 to 3 years, MODD’s thesis remains intact but fragile: sector conditions offer some support, while persistent losses, funding needs, and elevated earnings risk are central concerns. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.